Experimental substantiation of application of pegylated interferon α-2b oral formulation for therapy of enterovirAL infection
The purpose of the work is the study of the antiviral activity and some pharmacokinetic parameters of oral formulation of pegylated interferon α-2b (PEG-IFN α-2b) obtained by technology of electron-beam synthesis. Material and Methods. The antiviral activity of PEG-IFN α-2b against Coxsackie virus was studied in RD cells culture. To study the pharmacokinetics we used FITC-labeled PEG-IFN α-2b. Results and Discussion. PEG-IFN α-2b has a specific activity comparable to the original interferon. Bioavailability of PEG-IFN α-2b is 29.68% in intragastric administration. The drug is detected in the intestinal tissue in a sufficiently high concentration.